- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03254836
Sleep and Survival in Colorectal Cancer
Sleep-wake Rhythm in the Perioperative Period in Patients Admitted for Elective Radical Surgery for Colorectal Cancer: an Observational Prospective Cohort Study.
Objective The objective of the current trial is to investigate the effect of perioperative sleep and circadian rhythm on the natural course of survival among patient diagnosed with colorectal cancer. Concurrently, outcome measures like depression, fatigue, quality of life, and co-morbidity will be measured continuously in the short-, intermediate- and long-term period following diagnosis.
The a-priori hypothesis is that preoperative sleep and circadian disturbances is a prognostic marker of reduced overall survival. Likewise, preoperative sleep-wake disturbances at baseline are expected to result in overall universally reduced quality of life, increased depression and fatigue. Furthermore, development of sleep-wake disturbances in the postoperative period as compared to preoperative sleep-wake rhythm is expected to a prognostic marker of negative outcomes.
Target and study population The study population are all patients diagnosed with colorectal cancer in Region Zealand recruited consecutively from the trial initiation until study end each patient with an intended 5 year follow-up period. All available cases will be included in the trial.
Study design The study will be an observational prospective cohort study applying a longituditional repeated measure design.
Exposures and outcomes of interest The primary outcomes in the trial are sleep and circadian outcomes measured via actigraphy in the perioperative period.
Furthermore, cancer related survival and overall survival in the 5 year follow-up period is considered primary outcomes.
Secondary outcomes consist of consecutively measured depression, fatigue, quality of life, follow-up treatment and co-morbidity.
Exposure variables are primary related to the cancer, i.e. cancer stage, surgical treatment, oncological treatment, baseline co-morbidity and pharmacological treatment. Some of the secondary outcomes could be expected to serve as confounding or mediating factors.
Meaningful control for confounding will in the analysis phase be cancer stage and baseline sleep-wake rhythm status.
Sampling methods All available cases will be sought included in the trial. No formal sample size has been performed and continues inclusion into the trial will be performed during an 1,5 year period.
Statistical analyses The relationship between overall survival and baseline sleep-wake rhythm will be investigated using survival statistics and/or multivariate logistic regression.
Expected results The investigators expect to see a marked difference in overall survival among patients with sleep and circadian disturbances at baseline.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Zealand
-
Roskilde, Zealand, Danmark, 4000
- Department of Surgery, Zealand University Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Diagnosis of colorectal cancer as determined at the multi-disciplinary team conference.
- Admitted to elective radical surgery at the department of surgery at Zealand University Hospital
- Age above 18 years
- Informed consent
Exclusion Criteria:
- Non-ability to complete the study as assessed by the investigator
- Non-fluent in Danish.
- History of cognitive impairment (e.g. dementia)
- Paralysis or inability to answer study questioners electronically.
- Stadium 4 colonic adenocarcinoma with no surgical treatment options as determined at the multi-disciplinary conference.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
Colorectal cancer undergoing elective surgery
All patients eligible for elective curative intended surgery for colonic adenocarcinoma at Zealand University Hospital. Patients will recieve treatment as per standard of care. |
Elective radical surgery for adenocarcinoma.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Actigraphy
Tidsramme: Approximately 1 week preoperatively to 2 weeks postoperatively
|
Assessment of activity using accelerometor - Sleep and circadian assesment.
|
Approximately 1 week preoperatively to 2 weeks postoperatively
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Major Depression Inventory
Tidsramme: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Assesment of depression
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Insomnia Severity Index
Tidsramme: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Subjective sleep assesment
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Quality of life assesment
Tidsramme: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
EORCT-QLQ-C30
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Quality of life assesment
Tidsramme: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
EORCT-QLQ-CR29
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Mortality
Tidsramme: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Baseline registration and follow-up assessments
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Co-morbidity
Tidsramme: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Baseline registration and follow-up assessments
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Drug prescription history (Drug name and dosage)
Tidsramme: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Baseline registration and follow-up assessments
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Follow-up cancer treatment (Adjuvant chemotherapy, timing and duration)
Tidsramme: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Baseline registration and follow-up assessments
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Michael T Madsen, M.D., Department of Surgery, Zealand University Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Atferdssymptomer
- Psykiske lidelser
- Sykdommer i fordøyelsessystemet
- Sykdommer i nervesystemet
- Neoplasmer
- Dyssomnier
- Neoplasmer etter nettsted
- Nevrologiske manifestasjoner
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Kolonsykdommer
- Tarmsykdommer
- Yrkessykdommer
- Intestinale neoplasmer
- Rektale sykdommer
- Kronobiologiske lidelser
- Depresjon
- Søvnvåkenforstyrrelser
- Kolorektale neoplasmer
- Søvnforstyrrelser, døgnrytme
Andre studie-ID-numre
- MTM-V3
- SJ-600 (Annen identifikator: Region Zealand ethics Comittee)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Standard of care
-
University of Alabama at BirminghamTilbaketrukketFysisk aktivitetForente stater
-
University of Colorado, DenverRekruttering
-
Vanderbilt UniversityFullført
-
University of FloridaPatient-Centered Outcomes Research InstituteAktiv, ikke rekrutterendeProstatakreftForente stater
-
University of Maryland, BaltimoreFullført
-
Stryker EndoscopyRekrutteringSkulderskader | Kneskader | HofteskaderForente stater
-
University of OklahomaRekruttering
-
Adera Labs, LLCMemorial Sloan Kettering Cancer Center; Weill Medical College of Cornell... og andre samarbeidspartnerePåmelding etter invitasjonNeoplasmer i bukspyttkjertelenForente stater
-
NRG OncologyNational Cancer Institute (NCI); Alliance for Clinical Trials in Oncology; Eastern Cooperative Oncology Group og andre samarbeidspartnereRekrutteringHER2-positiv brystkreftForente stater, Puerto Rico